再生元制药公司(Regeneron Pharmaceuticals)就其研发的Fianlimab(一种Lag-3抑制剂)联合疗法,在一线治疗不可切除或转移性黑色素瘤患者中的三期临床试验提供了最新动态。
再生元制药公司(Regeneron Pharmaceuticals)就其研发的Fianlimab(一种Lag-3抑制剂)联合疗法,在一线治疗不可切除或转移性黑色素瘤患者中的三期临床试验提供了最新动态。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.